Inactivation Or Attenuation; Producing Viral Subunits Patents (Class 435/236)
-
Publication number: 20140302088Abstract: Embodiments herein report compositions, uses and manufacturing of dengue virus constructs and live attenuated dengue viruses. Some embodiments concern a composition that includes, but is not limited to, a tetravalent dengue virus composition. In certain embodiments, compositions can include constructs of one or more serotypes of dengue virus, such as dengue-1 (DEN-1) virus, dengue-2 (DEN-2) virus, dengue-3 (DEN-3) or dengue-4 (DEN-4) virus constructs. In other embodiments, constructs disclosed herein can be combined in a composition to generate a vaccine against more one or more dengue virus constructs that may or may not be subsequently passaged in mammalian cells.Type: ApplicationFiled: March 13, 2014Publication date: October 9, 2014Applicants: The Government of the United States of America as Represented by the Secretar, INVIRAGEN, INC.Inventors: Daniel T. Stinchcomb, Claire Y Huang, Richard M Kinney, Jill A Livengood
-
Publication number: 20140302077Abstract: Provided are live attenuated influenza A and B viruses as well as a composition, influenza A and B genes, a vector with a respective gene, a host cell comprising such vector, a method for preparing a live attenuated influenza A or B virus and a use of the influenza viruses as a vaccine. An influenza A virus contains a NP-gene, which includes a silent mutation at one or more positions selected from nucleotide 1467, nucleotide 1473, nucleotide 1500, nucleotide 1503, nucleotide 1512, nucleotide 1515, nucleotide 1518, nucleotide 1521, and nucleotide 1524 of SEQ ID No: 1. A PA gene includes a silent mutation at one or more positions corresponding to a position selected from nucleotides 2100 and 2103 of SEQ ID No: 3.Type: ApplicationFiled: August 28, 2012Publication date: October 9, 2014Applicant: Westfaelische Wilhelms-Universitaet MunesterInventors: Darisuren Anhlan, Christoph Scholtissek, Stephan Ludwig
-
Publication number: 20140302091Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.Type: ApplicationFiled: November 18, 2011Publication date: October 9, 2014Inventors: Dan T. Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
-
Publication number: 20140286980Abstract: The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include polynucleotide constructs that replicate in tissue culture and in host swine. The invention also provides for novel full length TTV genomes that can replicate efficiently in host animals and tissue culture.Type: ApplicationFiled: May 24, 2012Publication date: September 25, 2014Applicant: ZOETIS LLCInventor: Jacqueline Gayle Marx
-
Publication number: 20140255447Abstract: The present invention relates to compositions and methods for preparing cells from avian embryos. The invention also relates to cultures of such cells and the uses thereof, particularly for producing viruses such as MDV. The invention also relates to methods for the preparation of vaccines using such cells or viruses.Type: ApplicationFiled: March 5, 2013Publication date: September 11, 2014Applicant: BIOMUNE COMPANYInventors: SHARAD DEVIDASRAO SAWARKAR, CHRISTOPHER PATRICK GULLY
-
Publication number: 20140255445Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: ApplicationFiled: January 24, 2014Publication date: September 11, 2014Applicant: L'Universite Pierre Et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, Francois-Loic Cosset
-
Patent number: 8828406Abstract: Described herein are chimeric influenza virus gene segments and nucleic acid sequences encoding such chimeric influenza virus gene segments. A chimeric influenza virus gene segment described herein comprises packaging signals found in the non-coding and coding regions of one type of influenza virus gene segment and an open reading frame of a different type of influenza virus gene segment or fragment thereof. Also described herein are recombinant influenza viruses comprising two or more chimeric influenza virus gene segments and the use of such viruses in the prevention and/or treatment of influenza virus disease.Type: GrantFiled: July 29, 2010Date of Patent: September 9, 2014Assignee: Icahn School of Medicine at Mount SinaiInventors: Adolfo Garcia-Sastre, Peter Palese, Qinshan Gao
-
Patent number: 8821889Abstract: The invention provides for immunogenic compositions against West Nile Virus. The immunogenic compositions, in alternate embodiments, also include other equine pathogens. The West Nile Virus composition of the present invention advantageously provides for protection against North American Dominant West Nile Virus strains or isolates.Type: GrantFiled: August 31, 2009Date of Patent: September 2, 2014Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Kristina J. Hennessy, Phillip Wayne Hayes
-
Patent number: 8822192Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.Type: GrantFiled: May 12, 2010Date of Patent: September 2, 2014Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
-
Publication number: 20140242102Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: January 15, 2014Publication date: August 28, 2014Applicant: MEDIMMUNE, LLCInventors: Chin-Fen YANG, George KEMBLE, Chongguang LIU
-
Publication number: 20140242670Abstract: Described is a process for producing poliovirus, the process comprising: a) providing a serum-free suspension culture of cells, which are primary human retina (HER) cells that have been immortalized by expression of adenovirus E1 sequences, b) infecting the cells with poliovirus, at a cell density of between 2×106 cells/ml and 150×106 cells/ml, and c) harvesting poliovirus at a time of between 12 and 48 hours after infection.Type: ApplicationFiled: May 12, 2014Publication date: August 28, 2014Applicant: Crucell Holland B.V.Inventor: John A. Lewis
-
Publication number: 20140242669Abstract: The method described herein provides a novel platform utilizing yeast as a biological non-host system to express and assemble whole viruses for use as attenuated or killed vaccines.Type: ApplicationFiled: August 20, 2012Publication date: August 28, 2014Inventors: Arun K. Dhar, Daniel Bednarik
-
Patent number: 8815564Abstract: This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.Type: GrantFiled: March 16, 2009Date of Patent: August 26, 2014Assignee: Sanofi Pasteur Biologics, LLCInventors: Konstantin V. Pugachev, Alexander A. Rumyantsev, Maryann Giel-Moloney, Harold Kleanthous
-
Publication number: 20140234354Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5B (PPV5B) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.Type: ApplicationFiled: March 13, 2013Publication date: August 21, 2014Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA, Callie Ann VISEK
-
Publication number: 20140227225Abstract: The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.Type: ApplicationFiled: September 7, 2012Publication date: August 14, 2014Applicants: UWM RESEARCH FOUNDATION, INC., UNIVERSITY OF KANSASInventors: Jeffrey Aube, Brian Scott Jonathan Blagg, Kevin John Frankowski, David Norman Frick, Kelin Li, Frank John Schoenen
-
Patent number: 8802417Abstract: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.Type: GrantFiled: July 16, 2007Date of Patent: August 12, 2014Assignee: Crucell Holland B.V.Inventors: Giuseppe Marzio, Maria Grazia Pau, Dirk Jan Elbertus Opstelten, Alphonsus Gerardus Cornelis Maria Uytdehaag
-
Patent number: 8802109Abstract: A mutant herpesvirus that has a mutated gene that encodes a mutant infected cell protein 0 (ICP0) can be used in therapeutic methods as well as in diagnostics and research experiments. The encoded mutant ICP0 protein can be altered in one or more regions of ICP0 that are substantially conserved between two or more herpesviruses and/or within a phosphorylation region. The mutant herpesvirus can be substantially avirulent and immunogenic.Type: GrantFiled: March 29, 2010Date of Patent: August 12, 2014Assignees: University of Kansas, Southern Illinois UniversityInventors: David Davido, William Halford
-
Publication number: 20140220062Abstract: The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.Type: ApplicationFiled: September 4, 2012Publication date: August 7, 2014Inventors: Tong-Ming Fu, Dai Wang, Muneeswara Babu Medi
-
Publication number: 20140220660Abstract: The invention relates to culture conditions and methods that allow reproducible production of high titers of filamentous bacteriophage. Culture media comprising high titers of filamentous bacteriophage, as we methods of producing high titers of filamentous phage on a large scale are encompassed.Type: ApplicationFiled: July 27, 2012Publication date: August 7, 2014Inventors: Jason Wright, Marc Bradford, Frank Sugar, Tim Davies, Kevin Millsap
-
Patent number: 8796008Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF 30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: GrantFiled: May 31, 2013Date of Patent: August 5, 2014Assignees: Board of Regents, The University of Texas System, Rutgers, The State University of New JerseyInventors: Gaetano Montelione, Kalyan Das, Edward Arnold, Li-Chung Ma, Rong Xiao, Rei-Lin Kuo, Robert M. Krug, Karen Y. Twu
-
Patent number: 8795688Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.Type: GrantFiled: October 25, 2011Date of Patent: August 5, 2014Assignees: Sanofi Pasteur, Centers for Disease Control and PreventionInventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
-
Publication number: 20140205621Abstract: A new pantropic canine coronavirus (CCoV) strain, having reduced pathogenicity, and capable of eliciting an immune response, is described.Type: ApplicationFiled: June 26, 2012Publication date: July 24, 2014Inventors: Nicola Decaro, Vito Martella, Gabriella Elia, Canio Buonavoglia
-
Publication number: 20140205620Abstract: Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins and for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.Type: ApplicationFiled: June 1, 2012Publication date: July 24, 2014Applicant: THE BOARD OF REGENTS FOR OKLAHOMA STATE UNIVERSITYInventor: Antonius G.P. Oomens
-
Patent number: 8784838Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.Type: GrantFiled: March 15, 2013Date of Patent: July 22, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
-
Publication number: 20140186395Abstract: Described are methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Further described are methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for PRRSV. Methods of utilzing the cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of the virus for the purpose of vaccine production or diagnosis, are also described.Type: ApplicationFiled: March 13, 2013Publication date: July 3, 2014Applicant: Universiteit GentInventors: Peter Delputte, Hans Nauwynck, Hanne Van Gorp
-
Patent number: 8765444Abstract: Provided herein are methods and compositions for use in treating HSV-related conditions and diseases.Type: GrantFiled: July 15, 2010Date of Patent: July 1, 2014Assignee: The Board of Trustees of the University of IllinoisInventors: Bin He, Dustin Verpooten, Yijie Ma
-
Publication number: 20140170180Abstract: The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus.Type: ApplicationFiled: March 12, 2013Publication date: June 19, 2014Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Arun V. IYER, Dianna M. Murphy JORDAN, Abby Rae PATTERSON, Michael B. ROOF, Eric Martin VAUGHN, Joseph Gilbert VICTORIA, Callie Ann VISEK
-
Patent number: 8747860Abstract: The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems.Type: GrantFiled: July 5, 2012Date of Patent: June 10, 2014Assignee: Institute for Systems BiologyInventors: Carrie M. Rosenberger, Alan A. Aderem
-
Patent number: 8748174Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.Type: GrantFiled: January 20, 2012Date of Patent: June 10, 2014Assignee: MedImmune, LLCInventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
-
Publication number: 20140154216Abstract: The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: AMGEN INC.Inventor: Robert S. COFFIN
-
Publication number: 20140147890Abstract: The present invention relates to a genetically modified phage and use thereof in a method for producing a bio molecule of interest.Type: ApplicationFiled: July 6, 2012Publication date: May 29, 2014Applicant: DELPHI GENETICSInventor: Cedric Szpirer
-
Publication number: 20140142284Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain good healthy cells and the combination of any of these known or unknown proteins which contain any one of these good healthy cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Macrophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.Type: ApplicationFiled: October 17, 2013Publication date: May 22, 2014Inventor: Kieu Hoang
-
Patent number: 8728488Abstract: The invention encompasses nucleic acid molecules containing transcription units which encode the flavivirus M and E protein antigens. The flaviviruses include Japanese encephalitis virus, dengue, yellow fever virus and St. Louis encephalitis virus. The nucleic acids function to provide the M and E protein antigens when the nucleic acid resides in an appropriate host cell, especially when the host cell is the cell of a subject. The invention also encompasses a vaccine whose active agent is the nucleic acid. The invention further encompasses the cultured host cells when they contain within them nucleic acid molecules containing the transcription units. The invention in addition encompasses a method of immunizing a subject against flavivirus infection by administering to the subject an effective amount of a vaccine containing a nucleic acid molecule containing the transcription unit of the invention.Type: GrantFiled: December 28, 2011Date of Patent: May 20, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and PreventionInventor: Gwong-Jen J. Chang
-
Patent number: 8728793Abstract: The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.Type: GrantFiled: July 14, 2008Date of Patent: May 20, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jeffrey Glenn, Nam-Joon Cho, Curtis W. Frank, Kwang Ho Cheong
-
Patent number: 8722052Abstract: A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO 72, SEQ ID NO 79, SEQ ID NO 82, SEQ ID NO 85, SEQ ID NO 88, SEQ ID NO 91, SEQ ID NO 94, SEQ ID NO 97, SEQ ID NO 100, SEQ ID NO 103, SEQ ID NO 106, SEQ ID NO 109, SEQ ID NO 112, or SEQ ID NO 115. The peptide may comprise a delivery sequence such as a cationic peptide.Type: GrantFiled: November 17, 2009Date of Patent: May 13, 2014Assignee: The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the Holy and Undivided Trinity of Queen Elizabeth, near DublinInventors: Andrew Graham Bowie, Barry Noel Harrington, Tatyana Sergeevna Lysakova, Brian Keogh
-
Patent number: 8722059Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.Type: GrantFiled: August 19, 2011Date of Patent: May 13, 2014Assignee: MedImmune, LLCInventors: Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble
-
Publication number: 20140128383Abstract: The present invention relates to compounds, their use in the treatment or the prevention of viral disorders, including HIV.Type: ApplicationFiled: April 6, 2012Publication date: May 8, 2014Applicant: LABORATOIRE BIODIMInventors: Sophie Chasset, Francis Chevreuil, Benoit Ledoussal, Frédéric Le Strat, Richard Benarous
-
Publication number: 20140127249Abstract: Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant M2 sequence, and are useful in immunogenic compositions, e.g., as vaccines. Also disclosed herein are methods, compositions and cells for propagating the viral mutants, and methods, devices and compositions related to vaccination.Type: ApplicationFiled: June 21, 2012Publication date: May 8, 2014Applicant: FluGen, Inc.Inventors: Pamuk Bilsel, Yasuko Hatta
-
Publication number: 20140127261Abstract: Mutations in the central monomer contact interface of the flavivirus envelope protein which modulate the infectivity of the flavivirus are made. The mutations decrease the ability of the envelope dimer protein to dissociate.Type: ApplicationFiled: November 7, 2012Publication date: May 8, 2014Applicant: Southern Research InstituteInventor: Vladimir Yamshchikov
-
Patent number: 8716000Abstract: The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are suitable for the preparation of vaccines for a wide variety of pathogens, including viruses, bacteria and parasites. The disclosure also provides vaccine compositions (medicaments) containing a pathogen inactivated by exposure to hydrogen peroxide. Methods for eliciting an immune response in a subject by administering vaccine compositions containing a hydrogen peroxide inactivated pathogen are also provided.Type: GrantFiled: February 24, 2012Date of Patent: May 6, 2014Assignee: Oregon Health and Science UniversityInventors: Mark K. Slifka, Shirley Villadiego, Erika Hammarlund, Paul Yoshihara
-
Patent number: 8715999Abstract: The present invention relates to a mutant virus of the family flaviviridae, comprising a deletion in the capsid protein of at least 20 successive amino acids, without any further deletion, substitution or insertion mutation except of the amino acids next to the deletion, which may be substituted.Type: GrantFiled: February 6, 2009Date of Patent: May 6, 2014Assignee: Valneva Austria GmbHInventors: Franz X. Heinz, Christian Mandl, Petra Schlick, Andreas Meinke
-
Patent number: 8697089Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.Type: GrantFiled: March 15, 2013Date of Patent: April 15, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
-
Patent number: 8685412Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus alone or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.Type: GrantFiled: September 7, 2011Date of Patent: April 1, 2014Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Chengjin Huang, Jennifer Hess
-
Patent number: 8673612Abstract: The present invention relates to compositions and methods for producing an immune response or reaction, as well as to vaccines, kits, processes, cells and uses thereof. This invention more particularly relates to compositions and methods of using a synthetic viral particle to produce, modify or regulate an immune response in a subject. In a more preferred embodiment, the invention is based, generally, on compositions using synthetic viral particles as an adjuvant and/or vehicle to raise an immune response against selected antigen(s) or epitopes, in particular a cellular and/or a humoral immune response.Type: GrantFiled: October 25, 2001Date of Patent: March 18, 2014Assignee: L'Universite Pierre et Marie CurieInventors: David Klatzmann, Jean-Loup Salzmann, Bertrand Bellier, Charlotte Frisen, François-Loïc Cosset
-
Patent number: 8673613Abstract: The present invention encompasses methods of producing influenza B viruses in cell culture. The influenza B viruses may have desirable characteristics, such as enhanced replication in eggs and may be used, for example, in vaccines and in methods of treatment to protect against influenza B virus infection.Type: GrantFiled: June 18, 2008Date of Patent: March 18, 2014Assignee: Medimmune, LLCInventors: Hong Jin, Zhongying Chen
-
Publication number: 20140072591Abstract: The present invention relates to a live avirulent infectious pancreatic necrosis virus which has been shown to be genetically stable in biological studies. Fish exposed to said virus turn out positive for the virus without showing any signs of disease and the avirulent virus has also been shown to protect the fish against IPN for an extended period of time after administration. Thus, a vaccine comprising said virus and said virus for the prophylaxis or treatment of infectious pancreatic necrosis disease are also part of the present invention.Type: ApplicationFiled: March 14, 2012Publication date: March 13, 2014Inventors: Oystein Evensen, Gordon Ritchie, Trude Bakke Jossund, Stephen Mutoloki
-
Publication number: 20140065178Abstract: The present invention provides pseudoinfectious alphavirus particles and methods of making them and using them to produce an immune response to an alphavirus in a subject.Type: ApplicationFiled: February 1, 2012Publication date: March 6, 2014Applicant: UAB RESEARCH FOUNDATIONInventors: Ilya Frolov, Elena Frolova
-
Patent number: RE44916Abstract: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1, NS1, PA, PB1, and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition.Type: GrantFiled: November 29, 2012Date of Patent: May 27, 2014Assignee: Iowa State University Research Foundation, Inc.Inventors: Kyoung-Jin Yoon, Vickie Cooper
-
Patent number: RE45053Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.Type: GrantFiled: May 17, 2013Date of Patent: July 29, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
-
Patent number: RE45123Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.Type: GrantFiled: May 17, 2013Date of Patent: September 9, 2014Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai